CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals (Checkmate), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, today announced that it will present data at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago from April 14 – April 18. Data on Checkmate’s Phase 1b trial in subjects with advanced melanoma will be presented in an oral presentation in the Clinical Trials Plenary Session CTPL04 - Novel Immuno-oncology Strategies.
Oral Presentation Details:
Title: Intratumoral Toll-Like Receptor 9 (TLR9) Agonist, CMP-001,
In Combination With Pembrolizumab Can Reverse Resistance To PD-1
Inhibition In A Phase 1b Trial In Subjects With Advanced Melanoma
Abstract No: 10610
Presentation Number: CT144
Date/Time: April 17, 2018; 10:30 AM
Location: North Hall C, McCormick Place North (Level 1)
Checkmate Pharmaceuticals is a clinical stage company leveraging its expertise in the field of CpG oligonucleotides (TLR9 agonists) to specifically activate the innate arm of the immune system to stimulate a systemic antitumor cytolytic T cell (CTL) response. In combination with checkpoint inhibition, which blocks the tumor’s ability to mute the immune response, Checkmate’s TLR9 agonist triggers a powerful CTL response to recognize and ultimately destroy tumor cells.
Checkmate is a privately held company headquartered in Cambridge, MA.
Information regarding Checkmate is available at www.checkmatepharma.com.